Bausch Health Caps 2025 with $1.7B Debt Refinancing and 13% EBITDA Growth (BHC Q4 2025 Earnings Call)
🤖 Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Bausch Health successfully closed out a transformational 2025, delivering an 11th consecutive quarter of revenue and earnings growth while executing a massive $1.7 billion debt exchange. With near-term debt walls removed and the core gastroenterology and international franchises performing strongly, management is now prioritizing strategic business development and a patient approach to monetizing its 88% stake in Bausch + Lomb.
Salix Drives Broad-Based Q4 Margin Expansion
Bausch Health reported impressive consolidated fourth-quarter results, generating $2.796 billion in total revenue and driving adjusted EBITDA up 13% year-over-year to $1.52 billion. Excluding Bausch + Lomb, the core Bausch Health business grew revenue by 9% to $1.391 billion. This outperformance was heavily anchored by the Salix gastroenterology segment, which posted 9% top-line growth driven by consistent double-digit prescription demand for Xifaxan and a temporary sub-$50 million residual volume benefit linked to the company's recent exit from the Medicaid channel. Meanwhile, the International segment grew double-digits across EMEA and LatAm, reflecting effective regional commercial execution.
Unlocking Flexibility Through Balance Sheet Overhaul
The most pivotal strategic development for Bausch Health was its continued progress in restructuring a heavily levered balance sheet. During the fourth quarter, the company retired its $300 million accounts receivable facility and executed a massive $1.7 billion secured debt exchange. This transaction pushed $1.7 billion in maturities out four years and captured $80 million in debt discounts. Coupled with over $300 million in organic Q4 net debt reduction backed by $362 million in adjusted operating cash flow (excluding Bausch + Lomb), the company has now cleared all major debt maturity hurdles until the end of 2027.
Shibo Acquisition Positions Solta for 2026 Chinese Rebound
While the Solta medical aesthetics segment reported a slight 1% reported revenue contraction in the fourth quarter, this masked underlying strength. The headline weakness was entirely attributable to an accounting step-up and inventory transition tied to Bausch Health's strategic acquisition of Shibo, its full-service aesthetics distributor in China. Completed on December 1, this transaction temporarily dinged Q4 EBITDA by $10 million to $15 million as November sales were intentionally halted. However, by bringing distribution fully in-house, management expects Solta to deliver accelerating double-digit growth and reclaim China as its premier global market in 2026.
Patience Dictates Strategy for Bausch + Lomb Separation
With a newly secured maturity runway extending until 2028 (assuming Xifaxan maintains exclusivity), Bausch Health is fundamentally altering its approach to the structural separation of Bausch + Lomb. CFO JJ Charhon indicated that the added financial flexibility allows the Board to be patient rather than forcing a spin-off. Management explicitly noted that the most highly probable outcome for value maximization is now the direct sale of its 88% equity stake in Bausch + Lomb, executed opportunistically once the market adequately reflects Bausch + Lomb's improved operational execution and pipeline value.